GURU.Markets stock price, segment price, and overall market index valuation
The company's share price GDTC
Shares of CytoMed, a biotech company working in cell therapy, are extremely volatile. Their price reflects not revenue but investor expectations for the success of its scientific platform. The stock price is driven by news of clinical trials and partnerships.
Share prices of companies in the market segment - Cancer cure
CytoMed Therapeutics is a Singapore-based biopharmaceutical company developing gamma-delta T-cell-based cell therapy for cancer treatment. We've categorized it under "Cancer Treatment," and the chart below shows how the market is valuing this innovative approach in immuno-oncology.
Broad Market Index - GURU.Markets
CytoMed Therapeutics is a Singapore-based biopharmaceutical company developing gamma-delta T-cell-based cell therapy for cancer treatment. It is a component of the GURU.Markets index, and the chart below shows how its stock compares to the broader market.
Change in the price of a company, segment, and market as a whole per day
GDTC - Daily change in the company's share price GDTC
For CytoMed Therapeutics Limited, an immuno-oncology company, daily price change is a measure of extreme volatility. It reflects the market's reaction to clinical trial data and is a critical parameter in risk assessment formulas.
Daily change in the price of a set of shares in a market segment - Cancer cure
CytoMed Therapeutics Limited is a biotech company. This chart highlights the sector's extreme volatility. Comparison with GDTC's performance, which focuses on cell therapy, helps assess it as a high-risk asset.
Daily change in the price of a broad market stock, index - GURU.Markets
CytoMed is a biotech company developing cell therapy for cancer. Its shares are buzzing with anticipation of clinical trial results. These sharp, event-driven movements are part of a complex mosaic of stock market volatility.
Dynamics of market capitalization of the company, segment and the market as a whole over 12 months
Annual dynamics of the company's market capitalization GDTC
CytoMed Therapeutics' year-to-date performance is a story of next-generation cell therapy development. Its 12-month market cap depends entirely on progress in preclinical and early clinical trials of its gamma-delta T-cell and NK cell-based platform, which could offer a turnkey solution for cancer treatment.
Annual dynamics of market capitalization of the market segment - Cancer cure
As an early-stage biotech company, CytoMed is a high-risk bet on science. Its performance is completely disconnected from the sector and depends on news about the clinical trials of its cell therapy. Its stock price will reflect investors' speculative belief in the potential of its developments.
Annual dynamics of market capitalization of broad market stocks, index - GURU.Markets
Shares of CytoMed Therapeutics, a clinical-stage biotech, are detached from market cycles. Their trajectory isn't a reflection of the economy, but rather a reaction to news about drug trials. Sharp rises and falls amidst generally flat markets demonstrate that investors are betting on science, not business cycles.
Dynamics of market capitalization of the company, segment and the market as a whole for the month
Monthly dynamics of the company's market capitalization GDTC
CytoMed is a biotech company working in the field of cell therapy. Its monthly performance is typical for the sector: it depends entirely on progress in its scientific developments and clinical programs. Partnerships and licensing announcements are key.
Monthly dynamics of market capitalization of the market segment - Cancer cure
This chart reflects the dynamics of the biotech sector, particularly in cell therapy. For CytoMed, an early-stage company, this is the backdrop. Its volatile movements demonstrate how investor expectations surrounding breakthroughs in cancer treatment are impacting the entire industry.
Monthly dynamics of market capitalization of broad market stocks, index - GURU.Markets
CytoMed Therapeutics is a biopharmaceutical company developing gamma-delta T-cell-based cell therapy for cancer treatment. This is a cutting-edge but high-risk field. The overall market chart provides only background information, while CytoMed's performance is driven by clinical trial news, which is typical for the biotech sector.
Dynamics of market capitalization of the company, segment and the market as a whole for the week
Weekly dynamics of the company's market capitalization GDTC
CytoMed, a Singapore-based biotech developing innovative gamma-delta T-cell-based cancer therapy, is extremely news-sensitive. Its weekly stock price is a direct response to research progress, preclinical and early clinical trial data, and partnerships.
Weekly dynamics of market capitalization of the market segment - Cancer cure
CytoMed operates in the revolutionary cell therapy sector, where shared technological breakthroughs and regulatory decisions impact everyone. The success of one company can boost the entire segment. The chart will show whether GDTC is perceived by the market as a promising player or simply part of the mainstream.
Weekly dynamics of market capitalization of stocks of the broad market, index - GURU.Markets
CytoMed Therapeutics, as a biotech company, often ignores broader market trends. Its fate depends not on GDP or inflation, but on the results of clinical trials. The chart below clearly demonstrates how GDTC shares can rise or fall on their own news, while the overall market moves in a different direction.
Market capitalization of the company, segment and market as a whole
GDTC - Market capitalization of the company GDTC
CytoMed Therapeutics' stock price is a bet on cell-based cancer therapy. This Singapore-based company's market cap reflects investor hopes for its developments in gamma-delta T-cell therapy. Its price action reflects the market's speculative valuation of this cutting-edge, yet unproven, approach to immuno-oncology.
GDTC - Share of the company's market capitalization GDTC within the market segment - Cancer cure
CytoMed Therapeutics is a Singapore-based biotech company developing innovative gamma-delta T-cell-based cancer cell therapy. Its market share is based on this cutting-edge approach. The chart shows how the market perceives its potential to create universal, off-the-shelf cell therapy products.
Market capitalization of the market segment - Cancer cure
CytoMed Therapeutics is a Singapore-based biotech company developing cancer cell therapy based on unique donor cells. The chart below shows the market capitalization of the oncology sector. This represents an estimate of this innovative approach that could make cell therapy more accessible.
Market capitalization of all companies included in a broad market index - GURU.Markets
CytoMed is a Singapore-based biotech company developing cell therapy for cancer based on gamma-delta T cells. Its market capitalization is a bet on this innovative approach. The chart below shows the economic weight of the advanced cell therapy sector.
Book value capitalization of the company, segment and market as a whole
GDTC - Book value capitalization of the company GDTC
CytoMed Therapeutics' book value is capital for cell therapy. The company's foundation consists of patents for the technology for producing gamma-delta T cells and NK cells from donor blood to fight cancer, as well as its R&D laboratories. The chart below shows how the company is building a financial foundation for its innovative immunotherapy developments.
GDTC - Share of the company's book capitalization GDTC within the market segment - Cancer cure
CytoMed Therapeutics, which develops cell therapies, has key tangible assets in the form of cutting-edge R&D laboratories. The S_BCap_Seg graph shows its share of this innovative scientific infrastructure.
Market segment balance sheet capitalization - Cancer cure
CytoMed Therapeutics is a biotech company developing cell therapies for cancer. Its primary asset is its cutting-edge scientific platform, not its manufacturing facilities. The chart shows that its value is based on intangible assets and the potential of future drugs, which is typical of advanced biotechnology.
Book value of all companies included in the broad market index - GURU.Markets
CytoMed's book value is a cancer cell therapy platform. The Singapore-based company's assets include its R&D laboratories, gamma-delta T-cell culture equipment, and capital for clinical trials. This provides the material basis for creating an innovative, "off-the-shelf" cell product.
The ratio of market capitalization to book capitalization of a company, segment, and the market as a whole
Market capitalization to book capitalization ratio - GDTC
CytoMed Therapeutics is a biopharmaceutical company developing cell therapies for cancer treatment. Its book value is its cash reserves. Its market capitalization is the net bet investors make on the success of its unique approach, based on the use of donor cells, in future clinical trials.
Market to book capitalization ratio in a market segment - Cancer cure
CytoMed Therapeutics is a biopharmaceutical company developing cell therapies for cancer treatment. Its value depends on the success of clinical trials. The chart shows how market expectations for its platform compare to its tangible assets.
Market to book capitalization ratio for the market as a whole
CytoMed Therapeutics is a biopharmaceutical company developing cell therapies for cancer. Its value is based on the potential of its scientific platform. The chart shows how the market valuation reflects investors' faith in scientific breakthroughs, creating a huge gap with its book value, as is the case with many biotech companies.
Debts of the company, segment and market as a whole
GDTC - Company debts GDTC
CytoMed Therapeutics, a biopharmaceutical company developing cell therapies, uses debt to fund its research. This chart shows the capital raised to conduct preclinical and early clinical trials of its innovative cancer treatments. This represents an investment in cutting-edge, yet capital-intensive, science.
Market segment debts - Cancer cure
CytoMed Therapeutics is a preclinical biopharmaceutical company developing gamma-delta T-cell-based cancer cell therapy. Being in the earliest stages, it relies entirely on equity capital to fund its research. This chart reflects its financial position and the absence of traditional debt.
Market debt in general
Debt to book value of the company, segment and market as a whole
The company's debt to book capitalization ratio GDTC
CytoMed Therapeutics is a biopharmaceutical company developing cell therapies for cancer. This chart shows its reliance on debt. For a company in the clinical development stage, with no stable revenue, raising debt is a high risk that could either significantly accelerate research or lead to financial ruin.
Market segment debt to market segment book capitalization - Cancer cure
CytoMed Therapeutics is a biotech company specializing in cancer cell therapy. This biotech chart illustrates investors' appetite for risk and funding expensive research. It helps us understand how the company's financial position is typical for an industry where the stakes and potential rewards are extremely high.
Debt to book value of all companies in the market
CytoMed Therapeutics is a biotech company specializing in developing cell therapies for cancer treatment. This chart, which shows the market's debt-to-book value ratio, is important for assessing the investment climate in biotech. The market's willingness to finance companies with long and expensive development cycles determines CytoMed's future.
P/E of the company, segment and market as a whole
P/E - GDTC
CytoMed Therapeutics is a biotech company developing cancer cell therapy based on unique cells derived from donor blood. This chart reflects the company's belief in its innovative platform. Its value shows how willing investors are to invest in advance for a technology that promises to create a "ready-to-use" cell therapy for cancer treatment.
P/E of the market segment - Cancer cure
CytoMed Therapeutics, like other biotechs, belongs to a sector with high expectations. This chart shows the average P/E for this industry. Comparing the company's P/E to this benchmark allows us to understand how disruptive investors consider its cell therapy platform compared to other technologies being developed in the sector.
P/E of the market as a whole
CytoMed Therapeutics is a biopharmaceutical company developing cancer cell therapy using allogeneic (donor) cells. This could make treatment more affordable than autologous methods. This chart shows the risk appetite in biotech. The company's valuation depends on investors' confidence that its cell therapy approach will be successful and scalable.
Future P/E of the company, segment and market as a whole
Future (projected) P/E of the company GDTC
CytoMed Therapeutics is a biotechnology company developing a cell therapy for cancer based on gamma-delta T cells. The chart reflects speculative investor expectations. Future revenue is entirely dependent on the success of clinical trials and the potential of this innovative technology for the treatment of cancer.
%20P%2FE%20GDTC&width=1500&height=450&colorIndex=35&filename=GURU_Markets_-_Chart-of-the-companys-future-projected-PE-GDTC&v=1772527135075 "Chart of the company's future (projected) P/E GDTC")
Future (projected) P/E of the market segment - Cancer cure
CytoMed Therapeutics is a biopharmaceutical company developing a universal cell therapy based on gamma-delta T cells for the treatment of cancer. This chart shows its expected future profitability, allowing us to assess how highly the market values its innovative approach to creating "off-the-shelf" oncology drugs.
%20P%2FE%20graph%20of%20the%20market%20segment%20-%20Cancer%20cure&width=1500&height=450&colorIndex=36&filename=GURU_Markets_-_Future-projected-PE-graph-of-the-market-segment-Cancer-cure&v=1772527135105 "Future (projected) P/E graph of the market segment - Cancer cure")
Future (projected) P/E of the market as a whole
CytoMed Therapeutics is a Singapore-based biotechnology company developing innovative cell therapy for cancer treatment based on allogeneic (donor) cells. This cutting-edge science is at the forefront. The company's valuation is not tied to general market forecasts, but depends entirely on the success of its scientific platform.
%20P%2FE%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=37&filename=GURU_Markets_-_Chart-of-the-future-projected-PE-of-the-market-as-a-whole&v=1772527135137 "Chart of the future (projected) P/E of the market as a whole")
Profit of the company, segment and market as a whole
Company profit GDTC
CytoMed Therapeutics is a biopharmaceutical company specializing in the development of cellular immunotherapies for cancer based on gamma-delta T cells. Being in the preclinical stage, the company incurs significant research expenditures. This chart reflects its investment in developing an innovative cancer treatment platform with potential for future profitability.
Profit of companies in the market segment - Cancer cure
CytoMed Therapeutics is a preclinical biopharmaceutical company based in Singapore developing gamma-delta T-cell-based cell therapy for cancer. This chart shows the company's profitability in the oncology sector. The company's R&D costs impact its current overall profitability, but its innovative approach could become a new milestone in immunotherapy.
Overall market profit
CytoMed Therapeutics is a preclinical biopharmaceutical company developing cell therapies for cancer treatment. Its value depends entirely on the potential of its scientific developments and future research results. This chart reflects the state of the real economy, while CytoMed operates in the venture capital space, where success is unrelated to general market trends.
Future (predicted) profit of the company, segment and market as a whole
Future (projected) profit of the company GDTC
CytoMed Therapeutics is a biopharmaceutical company developing cell therapy for cancer using unique cells from umbilical cord blood. This chart reflects analysts' future earnings expectations, based on the long-term potential of its innovative platform. It demonstrates the market's confidence in the company's ability to successfully complete clinical trials.
%20profit%20of%20the%20company%20GDTC&width=1500&height=450&colorIndex=41&filename=GURU_Markets_-_Graph-of-future-projected-profit-of-the-company-GDTC&v=1772527135256 "Graph of future (projected) profit of the company GDTC")
Future (predicted) profit of companies in the market segment - Cancer cure
CytoMed Therapeutics is a biopharmaceutical company developing gamma-delta T-cell-based cellular immunotherapy for the treatment of cancer. This chart shows profitability forecasts for the oncology sector. It reflects expectations for new cell therapy platforms that could offer breakthroughs in cancer treatment.
%20profits%20of%20companies%20in%20a%20market%20segment%20-%20Cancer%20cure&width=1500&height=450&colorIndex=42&filename=GURU_Markets_-_Graph-of-future-predicted-profits-of-companies-in-a-market-segment-Cancer-cure&v=1772527135272 "Graph of future (predicted) profits of companies in a market segment - Cancer cure")
Future (predicted) profit of the market as a whole
CytoMed Therapeutics develops cell therapy for cancer. Like many biotech companies, CytoMed's overall market revenue forecast is important for its investment climate. Expectations of economic growth, reflected in the chart, increase investor risk appetite and facilitate fundraising for expensive research.
%20profits%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=43&filename=GURU_Markets_-_Chart-of-future-predicted-profits-of-the-market-as-a-whole&v=1772527135282 "Chart of future (predicted) profits of the market as a whole")
P/S of the company, segment and market as a whole
P/S - GDTC
CytoMed Therapeutics is a biopharmaceutical company developing cell therapies for cancer treatment. Being in the preclinical stage, it does not generate revenue. P/S will become an important indicator only after commercialization, reflecting the market's valuation of its innovative technology.
P/S market segment - Cancer cure
CytoMed Therapeutics is a biopharmaceutical company developing cell therapies for cancer treatment based on unique immune cells. Being in the preclinical stage, its valuation is based entirely on future potential. This chart reflects the investors' high expectations for their innovative platform for developing new cancer treatments.
P/S of the market as a whole
CytoMed Therapeutics is a biotech company developing cell therapies for cancer treatment. The company has no revenue, and its valuation is based on the potential of its scientific platform. This chart, showing the valuation of companies with real revenues, highlights CytoMed as a venture bet on the future of cellular immunotherapy.
Future P/S of the company, segment and market as a whole
Future (projected) P/S of the company GDTC
CytoMed Therapeutics is a biopharmaceutical company developing innovative gamma-delta T-cell-based cancer therapies. This chart reflects investor expectations for future revenue from this cutting-edge technology, betting that the company will be able to create an effective and commercially viable cancer treatment.
%20P%2FS%20GDTC&width=1500&height=450&colorIndex=47&filename=GURU_Markets_-_The-graph-of-the-companys-future-projected-PS-GDTC&v=1772527135355 "The graph of the company's future (projected) P/S GDTC")
Future (projected) P/S of the market segment - Cancer cure
CytoMed Therapeutics Limited is a preclinical biopharmaceutical company developing novel cell therapies for cancer based on gamma-delta T cells. This chart shows how the market views its future, though still hypothetical, potential. It compares it to other oncology companies, reflecting the high risks and expectations associated with its innovative technology.
%20P%2FS%20market%20segment%20graph%20-%20Cancer%20cure&width=1500&height=450&colorIndex=48&filename=GURU_Markets_-_Future-projected-PS-market-segment-graph-Cancer-cure&v=1772527135383 "Future (projected) P/S market segment graph - Cancer cure")
Future (projected) P/S of the market as a whole
CytoMed Therapeutics is a biopharmaceutical company developing cell therapies for cancer treatment based on unique cells derived from donor blood. This chart shows aggregate market expectations for future revenue, and the GDTC illustrates how cutting-edge immuno-oncology research is shaping investor expectations for new breakthroughs in cancer treatment.
%20P%2FS%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=49&filename=GURU_Markets_-_Chart-of-the-future-projected-PS-of-the-market-as-a-whole&v=1772527135391 "Chart of the future (projected) P/S of the market as a whole")
Sales of the company, segment and market as a whole
Company sales GDTC
CytoMed Therapeutics is a preclinical biopharmaceutical company based in Singapore, specializing in the development of cell therapies for the treatment of cancer. The company currently has no commercial products, so sales revenue is not reflected in this chart. Its activities are funded through research grants and investments.
Sales of companies in the market segment - Cancer cure
CytoMed Therapeutics is a biopharmaceutical company developing cell therapies for cancer treatment. At this stage, its revenue, if any, may come from licensing agreements or grants. This graph allows investors to assess external financial support, which is critical to its development.
Overall market sales
CytoMed Therapeutics is a biopharmaceutical company developing cell therapies for cancer. Its success depends on clinical trial results and regulatory approval. This overall market performance chart is not relevant for valuing a company whose value is created in the laboratory and determined by its potential to save lives.
Future sales volume of the company, segment and market as a whole
Future (projected) sales of the company GDTC
CytoMed Therapeutics is a biopharmaceutical company developing cell therapies for the treatment of cancer. Its revenue forecast depends on the success of clinical trials and the future commercial potential of its innovative approaches. This chart reflects analysts' speculative expectations for its oncology developments.
%20sales%20of%20the%20company%20GDTC&width=1500&height=450&colorIndex=53&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-the-company-GDTC&v=1772527135554 "Schedule of future (projected) sales of the company GDTC")
Future (projected) sales of companies in the market segment - Cancer cure
CytoMed Therapeutics is a biopharmaceutical company developing cell therapies for the treatment of cancer. This chart displays projected revenue for the entire oncotherapy segment. It provides an indication of how rapidly analysts expect this cutting-edge market to grow, which is critical to the future success of CytoMed's developments.
%20sales%20of%20companies%20in%20the%20market%20segment%20-%20Cancer%20cure&width=1500&height=450&colorIndex=54&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-companies-in-the-market-segment-Cancer-cure&v=1772527135597 "Schedule of future (projected) sales of companies in the market segment - Cancer cure")
Future (projected) sales of the market as a whole
CytoMed Therapeutics is a biopharmaceutical company developing cell therapies for cancer treatment. Its future depends on the success of clinical trials. This graph of overall market expectations does not directly impact demand, but reflects the investment climate, which is critical for raising funds for long-term and risky R&D projects in oncology.
%20sales%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=55&filename=GURU_Markets_-_Schedule-of-future-predicted-sales-of-the-market-as-a-whole&v=1772527135688 "Schedule of future (predicted) sales of the market as a whole")
Marginality of the company, segment and market as a whole
Company marginality GDTC
CytoMed Therapeutics is a biopharmaceutical company developing cell-based cancer therapies. This chart reflects the company's financial performance during preclinical and early clinical trials. It shows the company's investment in research, and its future ability to generate profits depends entirely on the success of its developments.
Market segment marginality - Cancer cure
CytoMed Therapeutics is a biopharmaceutical company developing novel cell therapies for cancer treatment based on gamma-delta T cells and NK cells. This chart illustrates the average profitability in the oncology biotechnology sector. It provides insight into the potential commercial value of CytoMed's innovative platform compared to other cancer treatment approaches.
Market marginality as a whole
CytoMed Therapeutics is a biotechnology company developing cell therapies for cancer treatment. This gross profit chart demonstrates the success of its existing business models, while CytoMed is investing in the future of medicine, where personalized treatments could revolutionize approaches to oncology.
Employees in the company, segment and market as a whole
Number of employees in the company GDTC
CytoMed Therapeutics is a biotechnology company developing cell therapies for cancer. Its small but growing team of scientists is working to develop innovative treatments. This chart shows how the company is building its scientific capacity to advance its developments through preclinical and clinical studies.
Share of the company's employees GDTC within the market segment - Cancer cure
CytoMed Therapeutics is a biopharmaceutical company focused on developing innovative cellular immunotherapies for cancer treatment. This chart highlights its cutting-edge scientific approach. It reflects the proportion of scientists and researchers working at the intersection of cell biology and oncology to create a new generation of "living" drugs that CytoMed brings together.
Number of employees in the market segment - Cancer cure
CytoMed Therapeutics is a biopharmaceutical company developing cell therapies for cancer. This chart shows employment in the oncology sector. The rapid growth of scientists in this field reflects the revolution in cancer treatment and the massive investment in cellular immunotherapy technologies, where CytoMed is seeking to carve out a niche.
Number of employees in the market as a whole
CytoMed Therapeutics Limited is a biopharmaceutical company developing cell therapies for the treatment of cancer. Immuno-oncology is one of the most promising areas in medicine. This chart reflects overall employment, and growth in these companies indicates the development of high-tech healthcare.
Market capitalization per employee (in thousands of dollars) of the company, segment, and market as a whole
Market capitalization per employee (in thousands of dollars) of the company GDTC (GDTC)
CytoMed Therapeutics is a cell therapy company. Its value reflects the hope of developing a new cancer treatment. This chart shows the enormous premium the market is placing on this hope. The high market capitalization per employee reflects the scientific team's potential to transform medicine.
%20of%20the%20company%20GDTC%20(GDTC)&width=1500&height=450&colorIndex=63&filename=GURU_Markets_-_Chart-of-market-capitalization-per-employee-in-thousands-of-dollars-of-the-company-GDTC-GDTC&v=1772527135968 "Chart of market capitalization per employee (in thousands of dollars) of the company GDTC (GDTC)")
Market capitalization per employee (in thousands of dollars) in the market segment - Cancer cure
CytoMed Therapeutics develops cell therapies to combat cancer. In this cutting-edge biotech field, market capitalization per employee is an indicator of market confidence in its scientific platform. A high market capitalization relative to the industry suggests that investors are pricing in the significant potential of its innovative treatments.
%20by%20market%20segment%20-%20Cancer%20cure&width=1500&height=450&colorIndex=64&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-by-market-segment-Cancer-cure&v=1772527135974 "Market capitalization per employee (in thousands of dollars) by market segment - Cancer cure")
Market capitalization per employee (in thousands of dollars) for the overall market
CytoMed Therapeutics is a biopharmaceutical company developing cell therapies for cancer, one of the most advanced fields in medicine. This chart reflects the enormous investor expectations for the ability of a small team of scientists to create and commercialize a new generation of anti-cancer drugs.
%20for%20the%20overall%20market&width=1500&height=450&colorIndex=65&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-for-the-overall-market&v=1772527136013 "Market capitalization per employee (in thousands of dollars) for the overall market")
Profit per employee (in thousands of dollars) for the company, segment, and market as a whole
Profit per employee (in thousands of dollars) of the company GDTC (GDTC)
CytoMed Therapeutics is a Singapore-based preclinical biotech company developing a cell therapy platform (gamma-delta T cells) for cancer treatment. This is pure science. This negative graph shows how much capital is being burned for each scientist working on this cutting-edge immunotherapy.
%20Chart%20GDTC%20(GDTC)&width=1500&height=450&colorIndex=66&filename=GURU_Markets_-_Company-Profit-Per-Employee-in-thousands-of-dollars-Chart-GDTC-GDTC&v=1772527136090 "Company Profit Per Employee (in thousands of dollars) Chart GDTC (GDTC)")
Profit per employee (in thousands of dollars) in the market segment - Cancer cure
CytoMed Therapeutics is a biopharmaceutical company developing gamma-delta T-cell-based cell therapy for cancer treatment. This chart highlights the potential of their innovative approach. It illustrates the enormous value a small team of scientists could generate if their cutting-edge treatment technology is successful, a key metric for biotech investors.
%20in%20the%20market%20segment%20-%20Cancer%20cure&width=1500&height=450&colorIndex=67&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-in-the-market-segment-Cancer-cure&v=1772527136114 "Chart of profit per employee (in thousands of dollars) in the market segment - Cancer cure")
Profit per employee (in thousands of dollars) for the market as a whole
CytoMed Therapeutics is a biopharmaceutical company specializing in the development of cell therapies (CAR-T) for cancer treatment. This R&D is cutting-edge but capital-intensive. This chart reflects the investment (expense) per highly qualified scientist working on the development of these "living drugs" through to their commercialization.
%20for%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=68&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-for-the-market-as-a-whole&v=1772527136133 "Chart of profit per employee (in thousands of dollars) for the market as a whole")
Sales to employees of the company, segment and market as a whole
Sales per company employee GDTC (GDTC)
CytoMed Therapeutics is a biotechnology company in preclinical development. This chart does not reflect commercial activity, as there is no revenue. It illustrates the scientific potential in the field of cell therapy. Future success will depend on the results of clinical trials and regulatory approval.
&width=1500&height=450&colorIndex=69&filename=GURU_Markets_-_Sales-chart-per-company-employee-GDTC-GDTC&v=1772527136153 "Sales chart per company employee GDTC (GDTC)")
Sales per employee in the market segment - Cancer cure
CytoMed Therapeutics (GDTC) is a biopharmaceutical company specializing in the development of cell therapies (based on NK cells and T cells) for the treatment of oncology. This chart shows the average revenue per employee in the pharmaceutical segment. For CytoMed, which is in the R&D stage, comparing to this benchmark (zero) highlights their focus on science rather than current sales.
Sales per employee for the market as a whole
CytoMed Therapeutics (GDTC) is a preclinical biotech company (cell therapy). It has no revenue. This figure is zero. Like NanoViricides (NNVC), it is a pure venture capital investment in a scientific platform that may (or may not) lead to a commercial product in many years.
Short shares by company, segment and market as a whole
Shares shorted by company GDTC (GDTC)
CytoMed Therapeutics is a Singapore-based preclinical biotech developing a cell therapy (NK cell therapy) for cancer treatment. This chart shows the odds against this early stage development. Bears believe the company has no chance of bringing its product to market and will burn through all of its investors' money long before any results are achieved.
&width=1500&height=450&colorIndex=72&filename=GURU_Markets_-_Short-Shares-Chart-for-the-Company-GDTC-GDTC&v=1772527136246 "Short Shares Chart for the Company GDTC (GDTC)")
Shares shorted by market segment - Cancer cure
CytoMed (GDTC) is a Singapore-based early-stage biotech developing advanced cell therapy (gamma-delta T) for cancer treatment. This chart highlights the pessimism in the sector. The growing short position in the sector is a bet that this technology is too complex and expensive. Investors doubt GDTC will be able to scale up production of living drugs and prove their effectiveness in trials.
Shares shorted by the overall market
CytoMed (GDTC) is a clinical-stage biotech based in Singapore. This business carries a dual risk. When this *global* pessimism indicator rises, investors (1) flee emerging markets and (2) sell off unprofitable biotechs, fearing financing risks.
RSI 14 indicator for a company, segment, and market as a whole
The company's RSI 14 indicator GDTC (GDTC)
CytoMed Therapeutics is a biotech company focused on cancer cell therapy, one of the hottest and most speculative areas in medicine. This chart shows the feverish anticipation. It heats up to extremes on news of treatment progress and just as quickly cools down on reports of delays or failures.
&width=1500&height=450&colorIndex=75&filename=GURU_Markets_-_RSI-14-indicator-chart-for-the-companys-stock-GDTC-GDTC&v=1772527136324 "RSI 14 indicator chart for the company's stock GDTC (GDTC)")
RSI 14 Market Segment - Cancer cure
CytoMed Therapeutics is a Singapore-based biotech developing allogeneic cell therapies based on gamma-delta T cells for the treatment of cancer. This is cutting-edge R&D. This chart reflects the overall sentiment in the oncology sector. It helps assess how overheated this entire speculative biotech segment is.
RSI 14 for the overall market
CytoMed (GDTC) is a biotech R&D company. Like everything in its sector, it's critically dependent on this schedule. Market euphoria offers the potential to easily raise hundreds of millions of dollars for research. Market panic risks running out of money before its breakthrough technologies reach patients.
Analyst consensus forecast for the company's share price, the segment, and the market as a whole
Analyst consensus stock price forecast GDTC (GDTC)
CytoMed Therapeutics is a Singapore-based biopharmaceutical company developing NK cell-based therapies for cancer treatment. This chart shows the speculative average 12-month price target from analysts, which is based almost entirely on their assessment of clinical trial data.
&width=1500&height=450&colorIndex=78&filename=GURU_Markets_-_A-chart-showing-analyst-consensus-forecasts-for-the-expected-stock-price.-GDTC-GDTC&v=1772527136458 "A chart showing analyst consensus forecasts for the expected stock price. GDTC (GDTC)")
The difference between the consensus estimate and the actual stock price GDTC (GDTC)
CytoMed is a Singapore-based biotech developing allogeneic (CAR-T) cell therapy for cancer. This chart measures the gap between the current price and the consensus target price. It shows how confident experts are in their early-stage R&D platform.
&width=1500&height=450&colorIndex=79&filename=GURU_Markets_-_A-chart-showing-the-difference-between-the-consensus-forecast-and-the-actual-stock-price.-GDTC-GDTC&v=1772527136510 "A chart showing the difference between the consensus forecast and the actual stock price. GDTC (GDTC)")
Analyst consensus forecast for stock prices by market segment - Cancer cure
CytoMed Therapeutics is a Singapore-based biotech company developing off-the-shelf (not personalized) cell therapies (NK cells) for cancer treatment. This chart shows the general expectations of analysts for the oncology sector. It reflects whether experts believe in the future of off-the-shelf cell therapies or consider the sector too risky.
Analysts' consensus forecast for the overall market share price
CytoMed Therapeutics is a Singapore-based biotech company developing NK cell-based therapies for cancer treatment. This chart shows the overall market "risk appetite." For CytoMed, operating in a high-risk sector and in an Asian jurisdiction, overall market optimism is important for attracting the capital needed to fund R&D.
AKIMA index of the company, segment and market as a whole
AKiMA Company Index GDTC
CytoMed is a Singapore-based clinical-stage biotech company. Their signature product is universal (allogeneic) CAR-T and NK cell therapies, which they are developing for cancer treatment. This chart is a pure indicator of their R&D, reflecting their progress in clinical trials and their speculative bet on universal cell therapy.
AKIMA Market Segment Index - Cancer cure
CytoMed Therapeutics (GDTC) is a Singapore-based biotech developing allogeneic (donor-derived) cell therapy based on gamma-delta T cells and NK cells for the treatment of cancer. The chart shows the average index for the segment, helping investors assess how this cutting-edge immunotherapy compares to the average risk level in the sector.
The AKIM Index for the overall market
CytoMed Therapeutics is a Singapore-based biotech company developing off-the-shelf cellular immunotherapies based on donor cells. This chart, showing the average (global/US) market share, serves as a benchmark. It helps assess how GDTC, an early-stage oncology development, compares to overall trends.
